Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6PD74
UPID:
AAGAB_HUMAN
Alternative names:
-
Alternative UPACC:
Q6PD74; B4DG44; Q6FI86; Q7Z5X9; Q9H0P1; Q9HAK0
Background:
Alpha- and gamma-adaptin-binding protein p34 plays a crucial role in the endocytic recycling of growth factor receptors, including the EGFR. This protein's involvement in cellular trafficking underscores its importance in maintaining cellular function and communication.
Therapeutic significance:
The association of Alpha- and gamma-adaptin-binding protein p34 with Keratoderma, palmoplantar, punctate 1A, a dermatological disorder, highlights its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies.